ImClone off on Erbitux delay

On Wednesday, IMCL was off $4.13 (12%) to $31.18 on 10.2 million shares after Tuesday's post-market announcement that the submission of an sBLA for Erbitux cetuximab to treat squamous cell carcinoma o...